Last updated: May 23, 2026
Acetazolamide supply chains split between (1) API producers and (2) finished-dosage manufacturers supplying tablets for commercial and institutional channels. The dominant procurement lever for quality and availability is whether vendors ship directly under cGMP with DMF/ASMF support (or hold an FDA-approved Drug Master File/CEP-based dossier in the EU).
What companies supply acetazolamide API?
API supply is the baseline constraint for acetazolamide tablets because most finished-dose producers rely on external procurement unless they vertically integrate synthesis.
API supplier landscape (typical structure)
Acetazolamide API is sourced from:
- Specialty generics and API manufacturers with DMF/ASMF filings for heteroaromatic carbonic anhydrase inhibitors.
- Indian and Chinese API producers that ship to global formulators under quality agreements.
- Vertically integrated generics that produce in-house only for select dosage strengths.
What to verify in API supplier selection
Procurement teams typically screen suppliers on:
- Regulatory dossier support (FDA DMF number, EU ASMF/CEP status)
- Batch release framework (QC for identity, assay, related substances, polymorph profile)
- Impurity controls (process-related impurities and genotox-relevant thresholds)
- Serialization and UDI capability (if shipping finished product, not API)
Who manufactures acetazolamide tablets (finished dosage) in the US?
U.S. market supply for acetazolamide tablets is typically provided by generic manufacturers with ANDA footprints and distribution through wholesalers and hospital formularies.
Finished-dose manufacturers: what drives eligibility
Finished-dose sourcing depends on:
- ANDA status with FDA (approved labels, strength coverage)
- Current manufacturing sites listed in the ANDA
- Inspection history for the site(s) producing acetazolamide tablets
- Continuity risk (single-site dependence is common for small-molecule legacy products)
Which excipients and dosage strengths affect supplier availability for acetazolamide?
Acetazolamide tablets are commonly supplied at legacy strengths and may include different excipient systems across manufacturers. Supply risk often concentrates in:
- Active ingredient procurement
- compression film-coating systems
- packaging formats (bottles vs unit-dose compliance packaging)
Dosage form and strength coverage to request from suppliers
Commercial buyers generally require confirmation for:
- Tablet strength(s) available on allocation
- Coating type and release characteristics (if applicable)
- Packaging configuration (NDC bottle count and cartonization)
How do API and finished-dose supplier qualification requirements work for acetazolamide?
Acetazolamide buyers for hospitals and commercial distributors treat qualification as a risk-management program rather than a one-time vendor onboarding.
Qualification package commonly required
- GMP certificate for API and/or drug product
- CoA and spec sheet aligned with pharmacopeial standards
- Stability data (API and finished product where relevant)
- Change control history (process, site, impurity profile)
- Regulatory filings evidence (DMF/ASMF reference for API or ANDA for drug product)
Auditing triggers used in practice
- Supply interruption or allocation
- Manufacturing site change
- Spec excursions (assay/impurity)
- Regulatory citations affecting the manufacturing site
What patents or regulatory exclusivity affect who can supply acetazolamide?
Acetazolamide is a legacy small molecule with long since matured patent and regulatory exclusivity. Supply is primarily governed by:
- ANDA approvals and ongoing cGMP compliance
- DMF/ASMF readiness for API procurement
- Current good manufacturing practice inspection outcomes
Practical implication for supplier strategy
Because acetazolamide is not typically protected by current exclusivity in the way newer branded products are, the limiting factors are supply chain reliability and quality dossier alignment, not IP barriers.
What Orange Book status matters for acetazolamide suppliers?
For generic sourcing decisions, teams use FDA’s Orange Book to validate:
- Approved strengths
- Application holders
- Patent listings tied to specific ANDAs
Procurement decision logic
- If an ANDA holder is active with the same strength, procurement paths are easier.
- If the Orange Book lists patents for certain label versions, buyer teams still source through approved product labels but may apply additional due diligence for supply chain continuity and litigated entries.
What generic entry risks exist for acetazolamide?
Since acetazolamide is widely generic, entry risk is less about first-to-market and more about:
- Manufacturing disruption
- API shortage events
- Quality system failures
- Regulatory actions affecting specific ANDA manufacturing sites
Where shortages usually originate
- API impurity excursions
- single-reactor or single-plant dependence
- packaging supplier constraints
- freight and customs delays for API shipped internationally
How does acetazolamide supply compare across US, EU, and UK sourcing?
US sourcing patterns
- ANDA-based finished dose supply dominates.
- API procurement hinges on DMF-backed material and supplier audits.
EU sourcing patterns
- ASMF/CEP-backed API is frequently used to support drug product dossier filings.
- Finished-dose supply is diversified across EU generics.
UK (post-Brexit) sourcing patterns
- Manufacturers still rely on robust quality documentation, often through EU-aligned dossiers and MHRA acceptance pathways.
What contract manufacturing and toll synthesis options exist for acetazolamide?
For companies lacking internal capabilities, acetazolamide supply is often supported by:
- toll API synthesis under DMF or dossier-protected quality systems
- CDMO tablet manufacturing with GMP-compliant blending, compression, and coating lines
- packaging-only vendors with compliance packaging for distributors
CDMO selection checklist for acetazolamide tablets
- Experience with small-molecule legacy formulations
- ability to meet tablet hardness, dissolution, and impurity specs
- validated coating process and stable supplier for excipients
How many manufacturers supply acetazolamide and what is the concentration risk?
Acetazolamide typically has multiple ANDA holders and multiple API sources globally, but concentration risk remains because:
- not all ANDA holders maintain the same production site
- some manufacturers limit production based on margin
- API plants can exit due to regulatory or cost pressures
Concentration risk indicators buyers monitor
- number of ANDA holders still manufacturing in current period
- number of active manufacturing sites per ANDA
- recent FDA warning letters or import alerts affecting acetazolamide tablet sites
- API supplier batch reliability history
Key Takeaways
- Acetazolamide supply is driven by API availability and finished-dose manufacturing site continuity, not by active exclusivity.
- Supplier qualification is focused on DMF/ASMF-backed documentation, impurity controls, and cGMP inspection readiness.
- Shortage and allocation events tend to trace back to API production constraints and tablet manufacturing site limitations.
- Procurement teams should validate supply continuity using Orange Book ANDA activity, manufacturing site status, and supplier batch release performance.
FAQs
- How do I verify an acetazolamide API supplier is registered for FDA use?
- What documentation is required to qualify acetazolamide tablet vendors under hospital GMP and quality systems?
- Which acetazolamide sourcing risks are most common: API impurity excursions or tablet manufacturing site downtime?
- How do DMF/ASMF filings influence acetazolamide API procurement for generic manufacturers?
- What Orange Book fields should be checked when selecting acetazolamide NDCs for supply planning?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- U.S. FDA. Drug Master Files (DMF). U.S. Food and Drug Administration.
- EMA. ASMF and CEP frameworks for active substances in EU drug dossiers. European Medicines Agency.
